87 results about "Caudal Vein" patented technology

The invention discloses a stem cell preparation for treating cirrhosis, which is prepared from stem cells from human umbilical cord placenta, normal saline containing seralbumin with concentration by volume being 0.5-5%, and low-molecular-weight heparin sodium with concentration being 50-701U/ml. When the stem cell preparation is transfused into a rat model with cirrhosis through a caudal vein, the effective dose of the stem cell preparation is 5*106 cells each time; and the effective dose of the stem cell preparation is 0.5-5*106 cells/ kg each time when the stem cell preparation is transfused into a patient with cirrhosis through a peripheral vein. After applied to rats with cirrhosis and patients with cirrhosis, the stem cell preparation can obviously improve the survival rate of the rats with cirrhosis and the patients with cirrhosis, retard and invert a cirrhosis process, improve a whole state and a liver function state, and promote pathological recovery of liver, thereby developing a new way to cell therapy for treating cirrhosis.

The invention belongs to the technical field of animal models, and particularly relates to a method for establishing a PDX model of high leukocyte leukemia, and the method comprises: screening a suitable clinical patient with the high leukocyte leukemia; using a COM. TEC blood cell separator to separate leukocytes from peripheral blood; separating and purifying mononuclear cells of the leukocytescollected from the peripheral blood for cell culturing to obtain leukemia cell suspension; preparing the PDX model of high leukocyte leukemia, to be more specific, firstly using X-ray for irradiationof mice, injecting the leukemia cell suspension to caudal veins of the mice, one week later, drawing blood of tails of the mice randomly for detection, and judging whether the model is successfully established according to detection results. The method for establishing the PDX model of the high leukocyte leukemia has a high success rate of modeling, disease manifestation and cell morphology of theconstructed PDX model of the mice can directly reflect the characteristics of high leukocyte leukemia cells.

The invention discloses a caudal vein joint intraperitoneal injectionfixing device which comprises a base, a cylinder, a front cover and a rear cover; the cylinder comprises a side plate and a slidingrail, a first sliding groove is formed in the side plate, the sliding rail and the side plate form an annular structure with the adjustable size, a track is connected to the side face of the front cover, a sliding hole is formed in the side plate, the track is slidably arranged inside the sliding hole, a locking mechanism is arranged at the side plate, the locking mechanism comprises a clamping base, a first clamping plate, a second clamping plate, a first spring and a first baffle, a second sliding groove is formed in the clamping base, the second clamping plate is slidably arranged inside the second sliding groove, the first clamping plate and the second clamping plate are arranged at the two sides of the track, the first baffle is hinged to the side plate, and the first baffle is provided with a circular bead and a limiting plate. A mouse is fixed so that an operator can perform the injection operation conveniently, force for clamping the mouse is fixed, and the phenomenon that blood circulation of the mouse is affected due to force changes or the mouse is killed in the testing process is avoided.

The invention relates to the technical field of biology, in particular to a leukemia mouse model based on a gene co-transfection technology and a preparation method thereof. The preparation method of the leukemia mouse model comprises the following steps: performing construction and packaging of K-ras mutants and AML1-ETO fusion gene lentivirus vectors; performing bone marrow cell separation and virus infection condition monitoring; implanting infection cells in a mouse to build a leukemia animal model; and performing model identification. The method of building the leukemia mouse model in a mode of utilizing caudal vein injection to lead in the manual site-directed mutagenesis K-ras mutants and AML1-ETO fusion gene lentivirus vectors is adopted initiatively. The leukemia mouse model is high in success rate, pathological characteristics are high in similarity to morbidity conditions of clinical leukemia, and the novel animal model can be provided for leukemia extramedullary infiltration mechanism research, leukemia medicine screening and gene and molecule target treatment.

The invention discloses an injecting and fixing device for a mouse. The device comprises a shell, wherein a fixing board is arranged in the shell, a mouse tail placement table is connected to the lower end of the shell through a connecting rod a, a rotating head is arranged on the mouse tail placement table, a connecting rod b is connected to one end of the rotating head, and an injecting device is connected to the other end of the rotating head. For the injecting and fixing device for the mouse, the fixing board is made of a soft material, the animal is fixed through the intrinsic joint bending of the animal, and adjustment can be carried out according to the body size of the animal; a sodium lamp is placed in the mouse tail placement table, so that the development for the caudal vein blood vessel can be realized, the heat generated by the sodium lamp can heat the mouse tail, so that the double effects including expanding the caudal vein blood vessel can be achieved; the injecting device is rotated through the connecting rod b with angle scales, the rotating head and a rotating rod, and the accurate positioning for an injection syringe is realized; the device provided by the invention is compact and portable in structure, is simple and easy to use, is good in repeatability, can realize injection through multiple ways, and has low requirement on the technology of experiment personnel.

The invention belongs to medical evaluation and detection technology field. It concerns in particular to the construction method of animal model for skin allergy therapeutic drug screen and skin allergy mechanism study. The skin allergic mouse model is built by injecting anti DNP IgE monoclonal antibody to BALB/c mouse caudal vein and provoking the action by making 2,4 dinitroflurobenzene as antigen. The model can imitate the skin allergy dynamic reaction whole process favorably, therefore, it can be used for the screening of skin allergy treating drug and study of skin allergy pathogenesis and drug action mechanism.

The invention relates to a method for preparing red cell outer membrane protein of left- -eyed flounders, Paralichthys olivaceus, comprising the following steps: blood is taken from the caudal vein of the left-eyed flounder; the Alsever gelation inhibitor and the peripheral blood of the left-eyed flounder are mixed; the blood is diluted by PBS buffer solution, mixed with separating medium and centrifugated at the temperature of 4 DEG C, and the deposit formed by the red cells at the bottom is centrifugally washed at the temperature of 4 DEG C by the PBS buffer solution to remove supernatant fluid; hypotonic buffer solution is added and kept at the temperature of 4 DEG C to fully swell the red cell so that the membrane is ruptured; the deposit of the red cell membrane of the left-eyed flounder is centrifugally collected at the temperature of 4 DEG C; the hypotonic buffer solution is added and then the deposit of the red cell membrane is scattered by a whirlpool mixer and centrifugally washed at the temperature of 4 DEG C; membrane protein lysis solution is added and stirred to fully cleave the red cell membrane of the left-eyed flounder; after centrifugating at the temperature of 4 DEG C, the supernate is the extracting solution of the red cell membrane protein of the left-eyed flounder; after being subpackaged, the extraction solution is preserved in an refrigerator at the temperature of minus 80 DEG C. Compared with the prior art, the method is simpler and more efficient, thereby not only ensuring the high efficiency of the preparation of membrane protein, but also maintaining the biological activity of the membrane protein.

The invention belongs to the field of natural medicinal chemistry, in particular to separation and extraction of natural anti-inflammatory drug molecules and an application thereof. The method comprises the following steps of extracting by acidic ethanol, decompressing and concentrating, adding water for dissolving, loading a sample in XAD-7 macroporous resin, eluting, collecting and concentrating, freeze-drying to extract the mangosteen pericarp anthocyanin. Experimental results show that mouse peritoneal fluid neutrophil exudation can be effectively inhibited after the mangosteen pericarp anthocyanin is injected into caudal vein of the mouse, the inhibition ratios are respectively 34%, 77% and 94% while the dosages are respectively 0.01, 0.1 and 1mg/ml. A laminar experiment using an in-vitro simulated capillary proves that the adhesion inhibition ratios of the mangosteen pericarp anthocyanin on neutrophil are respectively 45%, 71% and 89% while the dosages are respectively 0.01, 0.1 and 1mg/ml. Therefore, the anti-inflammatory activity of the mangosteen pericarp anthocyanin is proved, and the mangosteen pericarp anthocyanin as a novel anti-inflammatory drug has good application prospect.

The invention discloses an establishment method and application of a novel rat hypertension model. The disclosed establishment method of the novel rat hypertension model includes the following steps that 1, a human-body intron-derived 27nt-microRNA sequence is provided to construct its high expression plasmids; 2, the high expression plasmids in the step 1 is mixed with an X-treme GENEHP DNA transfection reagent in a certain proportion, after dilution with normal saline, the reagent is injected instantaneously in a SD rat at high speed from the caudal vein of the rat, the blood pressure of therat is increased to a high level, and the novel rat hypertension model is formed. The rat hypertension model is an effective animal disease model, can be used for verifying the influence of human-body intron-derived 27nt-MicroRNA on the blood pressure and vasodilator factors of the normal rat and screening antihypertensive drugs, and has wide application prospects.

The research group selects the optimum method for preparing a product of the invention, namely, enabling 100nM miR-21inhibitor transfected by lipo 2000 RNAimax to enter the stem cell. The stem cell product prepared by the method is enhanced in the capacity of secreting transforming growth factor TPF-beta 1, thus the capacity of inducing the T cell to differentiate towards regulatory T cells after co-culture of the cell and the T cell is enhanced, namely, the immunoregulation capacity of the stem cell is enhanced. In an in-vivo experiment, a medicine is adopted for inducing a mouse for establishing an acute enteritis model, the stem cell and a control cell which are transfected by miR-21 inhibitor are transfused into the body of the mouse through caudal vein by using the dosage of 1X10<6>, the result shows that the clinical symptoms and the immune indices of the mouse with stem cell group transfected by miR-21 inhibitor transfused are superior to those of the control cell group with transfusion, namely, the stem cell transfected by miR-21 inhibitor can be used for more effectively treating mouse enteritis. All in all, the stem cell with strong and stable effect is prepared, and experimental basis is provided for improving the application efficiency of the stem cell in clinic.

The invention discloses a doped self-assembled nano fiber structure and a preparation method thereof. Through synergistic interaction of molecules, nano fiber can obviously change near-infrared absorption of a cyanine dye, thereby obviously improving photo-acoustic performance and photo-thermal performance. Phosphatase response synchronous-assembly processes and diagnosis and treatment performance of assembly materials are verified respectively through cell and in vivo experiments. Particularly, through caudal vein injection, after 4 hours, tumors and peripheral normal tissues can be very clearly distinguished. According to the invention, the cyanine dye-doped nano fiber with in situ formation of tumor tissues can be used for fluorescence, photo-acoustic imaging and photo-thermal therapy.

The invention relates to Tabanusyao Macquart antithrombotic enzyme tablysin and a gene and application thereof, and belongs to the field of biomedicine. In the invention, a natural antithrombotic enzyme is separated by a biomechanical method and a coded gene of the enzyme is amplified; and a gene engineering product which has equivalent activity with natural protein is obtained by using an escherichia coli expression system. The Tabanusyao Macquart protease tablysin is active protein which is separated from a Tabanusyao Macquart salivary gland, wherein the molecular weight is 27KDa; and an amino acid sequence of the enzyme is shown as SEQ ID NO. 1. The gene of the Tabanusyao Macquart protease tablysin consists of a nucleotide sequence which is shown as SEQ ID NO. 2. Through the TabanusyaoMacquart protease tablysin, fibrinogen can be hydrolyzed, platelet aggregation can be suppressed, and carrageenin-induced rat caudal vein thrombosis can be suppressed; and the Tabanusyao Macquart protease tablysin does not have bleeding activity and can be applied to preparation of medicaments for treating thrombotic diseases.

The invention relates to application of nicotinamide adenine dinucleotide as an active ingredient in preparation of a drug for preventing or treating heart ischemic injuries. In experiments, caudal vein normal saline injection and a heart ischemia operation are carried out on rats in a control group, it is found through research results that a great number of apoptosis signals (TUNEL positive signals) appear on the hearts, while apoptosis signals of rats, on which caudal vein NAD+solution injection is carried out, in an experiment group can be effectively reduced.

The invention discloses an application of a PDL1-IgGFc fusion protein in inhibition of severe malaria morbidity, and belongs to the technical field of anti-malaria drug preparation. A fusion gene of a PDL1 molecule extracellular fragment and an IgG molecule Fc fragment is constructed, the fusion gene is constructed into adenovirus or is expressed in vitro, and the fusion protein is verified to be successfully expressed by a Western Blot method. In in-vitro cell experiments, the fusion protein can significantly inhibit ConA induced CD8+T cell activation; at the same time, in mice in-vivo cell experiments, through caudal vein injection of recombinant adenovirus for expressing the PDL1-IgGFc fusion protein, occurrence of cerebral malaria caused by infection of a plasmodium berghei ANKA strain can be significantly alleviated, and the survival time of mice is prolonged. The PDL1-IgGFc fusion protein is indicated to have a role in inhibiting severe malaria morbidity, and the inhibition role is involved with inhibition of CD8+T cell activation. The fusion protein provides a new drug selection for treatment of cerebral malaria and other severe malaria in clinic.

The invention discloses an electrically conductive macromolecular nano-material and an application of the electrically conductive macromolecular nano-material. According to the electrically conductive macromolecular nano-material, poly (3, 4-ethylidene dioxythiophene)/poly styrene sulfonic acid is taken as a substrate, wherein nano-particles formed by modifying polyacrylamide hydrochloride, polyacrylic acid and polyethylene glycol on the poly (3, 4-ethylidene dioxythiophene)/poly styrene sulfonic acid layer by layer. The nano-material is further connected with some fluorescent dyes or chemical drugs. The electrically conductive macromolecular nano-material can prepare photo-thermal therapeutic agent for treating cancer. The electrically conductive macromolecular nano-material has very strong optical absorption property in near-infrared area, forms a superbly high enrichment on the tumour position in the way of caudal vein injection and has very good treating effect under exposure to laser.

The invention discloses an application of carbon monoxide molecules in inhibition on acute rejection after skin grafting. According to a large number of cell tests, the inventor discovers that after the carbon monoxide molecules are dissolved into a dimethylsulfoxide (DMSO) solvent and placed into an organism, CO can be continuously released, so the carbon monoxide molecules can serve as exogenous CO donors. The skin of ICR mice and BALB/C mice can serve as a donor and a receptor; an allogeneic gene acute rejection model can be established; exogenous CO is injected into the caudal veins of the mice; and early intervention and the test are performed, so that the carbon monoxide release molecules have inhibition effect on the acute rejection after skin grafting. The carbon monoxide release molecules are used for inhibiting the acute rejection after skin grafting; the concentration is controlled relatively easily and correctly; during long-term use, the carbon monoxide release molecules are added conveniently; and the carbon monoxide molecules can serve as an immuno-inhibitor with high specificity, low toxicity and high efficiency.

The invention discloses a construction method of a chronic hepatitis E virus mouse model. In the method, HEV strains are derived from feces of chronically infected rhesus monkeys, and the rhesus monkeys continuously expel toxin for 93 weeks; after an HEV virus suspension is inoculated into BALB/c mice through caudal veins, HEV RNA can be continuously detected in feces and serum of the mice, and the HEV RNA has high virus copying property, and the continuous positive time can reach 36 weeks. The method for establishing the model is simple, can be used for researching the persistent infection mechanism of HEV, and can provide an important animal model for screening and evaluation of anti-HEV drugs.

The invention discloses an experimental mouse caudal vein micro injector, which comprises a syringe tube, a push rod, an electric pushing block, an electronic pump, a syringe needle base, a soft hose and a syringe needle, wherein the push rod is arranged in the syringe tube in a movable mode; and a micro flow meter is arranged on the electronic pump. The back end of the micro flow meter is connected to the syringe tube; the front end of the micro flow meter is provided with the flexible soft hose; the front end of the flexible soft hose is connected to the syringe needle base; the needle head is detachably arranged at the front end of the syringe needle base; and the syringe tube is detachably arranged on the electronic pump. A motor and a toothed strip are arranged on the electronic pump; the motor is meshed with the toothed strip by virtue of a gear; the electronic pushing block is arranged on the toothed strip; a sliding guide rail is arranged on the electronic pump; a display screen, a timer and a pushing block sliding cavity are arranged on the electronic pump; the display screen and the micro flow meter are connected; the timer and the motor are connected; and flow regulating buttons are arranged on the display screen. With the implementation of the micro injector disclosed by the invention, it can precisely control an injection speed and conduct metering, which is conducive to the accuracy of experimental results; the syringe needle does not easily become fallen and blood vessels are not easily damaged;and caudal vein injection can be completed by one person; therefore, the micro injector is labor-saving and is convenient to operate.

The invention discloses a method for carrying out anesthesia and blood drawing on Takifugu obscurus, which comprises the following operating steps of: firstly, adding pood water into a container; regulating the water temperature into 15 to 20 DEG C; adding clove oil into the container to prepare anesthetic solution with the weight ratio of the water to the clove oil of 99.98:0.02; placing the Takifugu obscurus into the anesthetic solution, wherein the anesthesia time is 2 to 5 minutes; drawing blood by a syringe at the caudal vein, wherein the blood drawing time is 1 to 1.2 minutes; and after drawing blood, transferring the Takifugu obscurus into a temporary culturing pood for revival. According to the invention, aiming at the physiological property of the Takifugu obscurus, the method is successfully used for carrying out anesthesia and blood drawing on the Takifugu obscurus, has low cost, is simple and convenient to operate, has small damage to the fish body and has a large blood drawing quantity.